Evidence map›Paper›PMID 35274366›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022

Prevalence of most common skin diseases in Europe: a population-based study.

M A Richard, C Paul, T Nijsten, P Gisondi, C Salavastru, C Taieb, M Trakatelli, L Puig, A Stratigos, EADV burden of skin diseases project team

Open access · hybridAbstract read
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 5 pooled it
35.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 5 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. AAVrh32.33 capsid demonstrates unexpected dermal tropism regardless of immunodominant epitope.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 7 countries.

M A RichardCEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Dermatology Department, University Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, Marseille, France.ORCID https://orcid.org/0000-0002-0870-9132
C PaulService de Dermatologie, Université de Toulouse et CHU, Toulouse, France.
T NijstenDepartment of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
P GisondiSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.ORCID https://orcid.org/0000-0002-1777-9001
C SalavastruDepartment of Pediatric Dermatology, Colentina Clinical Hospital, Bucharest, Romania.
C TaiebPatients priority, EMMA, Fontenay Sous-Bois, France.ORCID https://orcid.org/0000-0002-5142-2479
M TrakatelliSecond Department of Dermatology and Venerology of Aristotle School of Medicine Papageorgiou Hospital, Thessaloniki, Greece.
L PuigDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-6083-0952
A StratigosDepartment of Dermatology, Andreas Syggros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
EADV burden of skin diseases project team
Aix-Marseille Université · FRErasmus MC · NLNational and Kapodistrian University of Athens · GRPapageorgiou General Hospital · GRPatients First · USSpitalul Clinic Colentina · ROUniversitat Autònoma de Barcelona · ESUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity of Verona · IT

Funding

EADV
6 · The paper itself

Abstract

backgroundThe assessment of the prevalence of diseases is of primary importance in planning health policies. No complete data on the prevalence of skin diseases across European countries are available.

objectiveTo estimate the prevalence of the most frequent skin conditions or diseases in 27 European countries (24 EU countries, plus Norway, Switzerland, and the United Kingdom).

methodsWe conducted a population-based study on representative and extrapolable samples of the general population aged 18 years or more in each of the 27 countries surveyed. Participants were selected using stratified, proportional sampling with a replacement design. Data were collected using a web-based online survey. All participants were asked to fill in a questionnaire with sociodemographic data and to declare if they have had one or more skin conditions or diseases during the previous 12 months.

resultsA total of 44 689 participants from 27 countries responded to the questionnaire, 21 887 (48.98%) men and 22 802 (51.02%) women. The proportion of participants who reported having suffered from at least one dermatological condition or disease during the previous 12 months was 43.35% (95% CI: 42.89%, 43.81%). The projection in the total population of the 27 countries included in the study resulted in 185 103 774 individuals affected by at least one dermatological condition or disease. Accordingly, we can estimate that more than 94 million Europeans complain of uncomfortable skin sensations like itch, burning, or dryness. The most frequent conditions were fungal skin infections (8.9%), acne (5.4%), and atopic dermatitis or eczema (5.5%). Alopecia, acne, eczema, and rosacea were more common in women, whereas men were more likely to suffer from psoriasis and sexually transmitted infections.

conclusionSkin diseases are an important public health concern. Their high prevalence has to be taken into account in planning access to dermatological care to address patient needs.

Indexed as

Acne VulgarisEczemaSkin DiseasesEuropeFemaleHumansMalePrevalence

Identifiers

PMID35274366
PMCPMC9415115
OpenAlexW4220924178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.